share_log

Universe Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

Universe Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)

大自然藥業 | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/09/21 04:18

Moomoo AI 已提取核心訊息

Universe Pharmaceuticals reported a significant decline in financial performance for H1 2024, with revenue dropping 30.2% to $12.9M from $18.5M in H1 2023. The company's TCMD product sales decreased by 26.7% to $6.9M, while third-party product sales fell 33.9% to $6.0M. Gross margin declined to 26.2% from 33.2% year-over-year.The company recorded a substantial net loss of $13.1M, compared to a net loss of $715,427 in H1 2023, primarily due to realized losses and fair value changes in short-term investments totaling $10.7M. Operating expenses decreased by 14.5% to $5.1M, though selling expenses increased 74% to $4.1M due to increased advertising and marketing efforts.As of March 31, 2024, the company maintained $8.9M in cash and $2.5M in short-term investments. The company has contractual obligations totaling $22.0M, including $6.5M in debt obligations and $13.3M in capital expenditure commitments for ongoing construction projects. Management believes current resources are sufficient to meet working capital needs for the next 12 months.
Universe Pharmaceuticals reported a significant decline in financial performance for H1 2024, with revenue dropping 30.2% to $12.9M from $18.5M in H1 2023. The company's TCMD product sales decreased by 26.7% to $6.9M, while third-party product sales fell 33.9% to $6.0M. Gross margin declined to 26.2% from 33.2% year-over-year.The company recorded a substantial net loss of $13.1M, compared to a net loss of $715,427 in H1 2023, primarily due to realized losses and fair value changes in short-term investments totaling $10.7M. Operating expenses decreased by 14.5% to $5.1M, though selling expenses increased 74% to $4.1M due to increased advertising and marketing efforts.As of March 31, 2024, the company maintained $8.9M in cash and $2.5M in short-term investments. The company has contractual obligations totaling $22.0M, including $6.5M in debt obligations and $13.3M in capital expenditure commitments for ongoing construction projects. Management believes current resources are sufficient to meet working capital needs for the next 12 months.
大自然藥業報告了2024年上半年財務業績的顯著下降，營業收入從2023年上半年1,850萬美元下降了30.2%，降至1,290萬美元。該公司的TCMD產品銷售下降了26.7%，降至690萬美元，而第三方產品銷售下降了33.9%，降至600萬美元。毛利率同比下降至26.2%，前一年爲33.2%。該公司記錄了1,310萬美元的重大淨損失，而2023年上半年淨損失爲715,427美元，主要由於實現的虧損和短期投資公允價值變動共計1,070萬美元。營業費用下降了14.5%，降至510萬美元，儘管銷售費用因增加廣告和市場營銷投入而增加了74%，達到410萬美元。截至2024年3月31日，公司保持890萬美元的現金和250萬美元的短期投資。公司有合同義務總計2,200萬美元，包括650萬美元的債務義務和1,330萬美元的資本支出承諾，用於持續施工項目。管理層相信，公司當前的資源足以滿足未來12個月的營運資金需求。
大自然藥業報告了2024年上半年財務業績的顯著下降，營業收入從2023年上半年1,850萬美元下降了30.2%，降至1,290萬美元。該公司的TCMD產品銷售下降了26.7%，降至690萬美元，而第三方產品銷售下降了33.9%，降至600萬美元。毛利率同比下降至26.2%，前一年爲33.2%。該公司記錄了1,310萬美元的重大淨損失，而2023年上半年淨損失爲715,427美元，主要由於實現的虧損和短期投資公允價值變動共計1,070萬美元。營業費用下降了14.5%，降至510萬美元，儘管銷售費用因增加廣告和市場營銷投入而增加了74%，達到410萬美元。截至2024年3月31日，公司保持890萬美元的現金和250萬美元的短期投資。公司有合同義務總計2,200萬美元，包括650萬美元的債務義務和1,330萬美元的資本支出承諾，用於持續施工項目。管理層相信，公司當前的資源足以滿足未來12個月的營運資金需求。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Citius Oncology
    CTOR
    -- 0.930
    腦再生科技
    RGC
    -- 31.880
    正業生物
    ZYBT
    -- 5.380
    Emergent BioSolutions
    EBS
    -- 4.860
    Ironwood醫藥
    IRWD
    -- 1.470
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日